Parkinson's Disease Treatment Market Aging Populations and Advancements in Deep Brain Stimulation, Gene Therapy, and Medications Fuel Marke ...

GOTHENBURG, SE / ACCESS Newswire / February 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 12, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company d ...

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The Parkinson’s disease (PD) market across the seven major markets (7MM) is projected to reach $7.9b in 2033 at a compound annual growth rate of 8.9%, according to GlobalData.

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...

( MENAFN - IANS) New Delhi, Feb 4 (IANS) The global Parkinson's disease (PD) market is expected to grow to $7.9 billion by 2033 from $3.4 billion in 2023, according to a report.

The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and ...

A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...